Integra LifeSciences Holdings Corporation (IART)
| Market Cap | 5.88B |
| Revenue (ttm) | 1.38B |
| Net Income (ttm) | 170.11M |
| Shares Out | 84.50M |
| EPS (ttm) | 1.99 |
| PE Ratio | 34.85 |
| Forward PE | 25.13 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 15 |
| Last Price | $69.45 |
| Previous Close | $69.60 |
| Change ($) | -0.15 |
| Change (%) | -0.22% |
| Day's Open | 69.86 |
| Day's Range | 69.26 - 70.08 |
| Day's Volume | 210,164 |
| 52-Week Range | 42.12 - 77.40 |
Integra's (IART) CSS segment too reflects a gradual recovery in procedure-based market as well as an improvement in hospital capital spending during the first quarter.
Integra (IART) reported earnings 30 days ago. What's next for the stock?
PRINCETON, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will host an Investor Day meeting from 8:30 a.m. ...
PRINCETON, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will host an Investor Day meeting from 8:30 a.m. ...
Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.
Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Integra (IART) delivered earnings and revenue surprises of 23.21% and 2.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Integra Lifesciences (NASDAQ:IART) rose 1.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 43.75% over the past year to $0.69, whi...
PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first ...
The acquisition of ACell, and faster recovery growth rate in Japan and China are likely to have helped recover Integra's first-quarter 2021 performance.
Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.
Integra (IART) is optimistic about maintaining its strength in its international business, along with its portfolio optimization strategy.
PRINCETON, N.J., April 19, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company and manufacturer of SurgiMend Collagen Matrix, to...
PRINCETON, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2021 financial resul...
PRINCETON, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced the appointment of Shaundra Clay...
Investors are optimistic about Integra LifeSciences (IART) stock, owing to its strong international business growth and focus on portfolio optimization.
Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically,
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Most of Integra's (IART) franchises or products succeed in sustaining the momentum after returning to growth in the third quarter.
After the rise of 10-year yields terrified investors, the indices “reverse rotated” back into the Nasdaq and out of the Dow. Make the most of this market with today's top buys, from Q.ai's Artificial In...
Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically.
Integra (IART) fourth-quarter 2020 revenues fell 1.6% year over year to $388.6 million but rose 5% sequentially.
PRINCETON, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it is participating in the ...
Integra (IART) delivered earnings and revenue surprises of 13.51% and 0.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Integra Lifesciences (NASDAQ:IART) moved higher by 0.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 23.53% year over year to $0....
Integra Lifesciences Holdings Corp (NASDAQ: IART) reported Q4 adjusted EPS $0.84 better than the consensus estimate of $0.73 and revenues of $388.6 million in line with expectations. Revenues declined 1...
PRINCETON, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full-year ended December 31, 2020,...
The acquisition is expected to remain accretive to Integra's (IART) revenue growth and adjusted gross margins.
PRINCETON, N.J., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it completed the previously-discl...
Integra's (IART) sales improvement in the fourth quarter is likely to have been boosted by on-going business recovery.
PRINCETON, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fo...
Integra (IART) does not expect the selloff to have a material impact on its 2020 results.
PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has completed its previously a...
Integra (IART) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.
Integra (IART) expects to close the ACell acquisition in the first quarter of 2021, subject to fulfilment of closing conditions.
PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Peter Arduini, president an...
Integra LifeSciences is in the late stages of a transition period, rounded off by the recent divestiture of the orthopaedics segment, to be closed next year. The company has had a strong sequential quar...
Let's see if Integra LifeSciences (IART) stock is a good choice for value-oriented investors right now from multiple angles.
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Integra's (IART) third-quarter 2020 results reflect mixed segmental performance with strong recovery trends due to coronavirus-led business disruptions.
Integra LifeSciences Holdings Corporation (IART) CEO Peter Arduini on Q3 2020 Results - Earnings Call Transcript
Integra (IART) delivered earnings and revenue surprises of 40.35% and 0.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Integra Lifesciences (NASDAQ:IART) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 17.65% year over year to $0.80, which beat the estima...
PRINCETON, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third q...
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IART vs. ABMD: Which Stock Is the Better Value Option?
Integra's (IART) sales improvement in the third quarter is broad-based across the major franchises as per preliminary statement.
PRINCETON, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary th...
Smith & Nephew SNN, +2.16% SN, -0.91% said it's buying the extremity orthopedics unit of Integra LifeSciences IART, -0.40% ...
About IART
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial... [Read more...]
| Industry Medical Devices | IPO Date Aug 16, 1995 |
| CEO Peter Arduini | Employees 3,700 |
| Stock Exchange NASDAQ | Ticker Symbol IART |
Financial Performance
In 2020, IART's revenue was $1.37 billion, a decrease of -9.60% compared to the previous year's $1.52 billion. Earnings were $133.89 million, an increase of 166.71%.
Analyst Forecasts
According to 14 analysts, the average rating for IART stock is "Buy." The 12-month stock price forecast is 77.55, which is an increase of 11.66% from the latest price.